« Previous Next » Seminars in Oncology
Volume 32, Issue 3 , Pages 336-350 , June 2005

New Agents in the Management of Advanced Mesothelioma

Pemetrexed: mechanism of action (see text for explanation).

Pemetrexed: mechanism of action (see text for explanation).
- Full-Size Image
- Download to PowerPoint
Survival curve relative to the EMPHACIS trial, showing a statistically significant longer median survival time for the patients who received the Pemetrexed/cisplatin combination versus cisplatin alone

Survival curve relative to the EMPHACIS trial, showing a statistically significant longer median survival time for the patients who received the Pemetrexed/cisplatin combination versus cisplatin alone: 12.1 months versus 9.3 months, respectively (hazard ratio [HR] = 0.77; P = .020).
- Full-Size Image
- Download to PowerPoint
Relative risk of select toxicities calculated for both the intent-to-treat population (randomized and treated, n = 448) and for the fully folate- and vitamin B12-supplemented subgroup (patients supple

Relative risk of select toxicities calculated for both the intent-to-treat population (randomized and treated, n = 448) and for the fully folate- and vitamin B₁₂-supplemented subgroup (patients supplemented with FA/B₁₂; n = 331) within the EMPHACIS trial. SAE, serious adverse effects; FA, folic acid.
- Full-Size Image
- Download to PowerPoint